Exceptionally Low-Cost Downstream Processing Using Column-Less Purification Technology

The team at Isolere Bio, a Donaldson Life Sciences business in the U.S. will develop a biomanufacturing platform for low-cost production of monoclonal antibodies based on a multidomain synthetic protein enabling both capture and purification of the antibody in a chromatography-free process. The synthetic protein includes an antibody-binding affinity tag, and it enables liquid-liquid phase separation and selective concentration of the bound antibody. Key steps in the biomanufacturing process will be targeted to decrease costs and improve performance. This includes high-throughput experiments to identify conditions that improve the recycling of the synthetic protein, as well as tests to optimize the removal of viral contaminants during the purification process. Subsequently, larger-scale production will be piloted to identify the critical parameters required to scale up the platform.